Company profile
Statera Biopharma, Inc.
OTC: STAB · Healthcare · Biotechnology
#835 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 15GM —SS 27
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), Piotroski F · ↓ filing timeliness, return on assets
Methodology →Revenue TTM
$3.7M
Rev growth YoY (TTM)
+2028.3%
Net income (FY)
-$101.9M
Employees
46
as of 2026-08-30
Market cap
$7.1k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.5M$1.5M2021
Net income-$101.9M-$101.9M2021
Operating income-$98.3M-$98.3M2021
Total assets$21.2M$21.2M2021
Liabilities$22.7M$22.7M2021
Equity-$1.6M-$1.6M2021
Revenue trend
FY2011 – FY2021 · USD
FY11
FY11
FY11
FY14
FY19
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Statera Biopharma, Inc.’s revenue?
Statera Biopharma, Inc. booked $1.5M in FY2021 revenue, growing 466% year over year — faster than 94% of Healthcare companies we track, at a -6849.3% net margin.
Peers · Healthcare
Molecule Holdings Inc.——New Leaf Ventures Inc——St. Joseph, Inc.67BXsovt Brands, Inc.——Glow Lifetech Corp.——American Green, Inc.51DNeighbors
Larimer →Key facts
CEOBlake Hawley
SectorHealthcare
IndustryBiotechnology
HeadquartersFort Collins, CO
ExchangeOTC: STAB
Employees46
IPO date2021-07-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.